ZVSA OTC
ZyVersa Therapeutics, Inc.
1W: -19.2%
1M: -19.4%
3M: -48.1%
YTD: -40.7%
1Y: -44.1%
3Y: -99.8%
$0.08
+0.00 (+0.00%)
Weekly Expected Move ±16.8%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$7K
+33.3% ▲
Operating Income
-$9.1B
-63258.8% ▼
Net Income
-$9.4B
-9476.4% ▼
EPS (Diluted)
$-8.48
+99.2% ▲
EBITDA
-$9.1B
-8380.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $10K | $10K | $10K | $10K | $7K |
| Gross Profit | -$10K | -$10K | -$10K | -$10K | -$7K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $6M | $2M | $5M | $3M | $1.8B |
| SG&A Expenses | $5M | $6M | $8M | $11M | $7.4B |
| Operating Expenses | $12M | $8M | $14M | $14M | $9M |
| Operating Income | -$12M | -$8M | -$14M | -$14M | -$9.1B |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $516K | $821K | $428K | $0 | $270K |
| Income Before Tax | -$13M | -$8M | -$15M | -$108M | -$9.4B |
| Tax Expense | $0 | $0 | -$745K | -$9M | -$7M |
| Net Income | -$13M | -$8M | -$14M | -$98M | -$9.4B |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-272.45 | $-173.66 | $-930.25 | $-1089.66 | $-8.48 |
| EBITDA | -$12M | -$7M | -$14M | -$108M | -$9.1B |
| Shares Outstanding | 46552 | 46552 | 25948 | 97503 | 1M |